Aldosterone deficiency prevents high-fat-feeding-induced hyperglycaemia and adipocyte dysfunction in mice

Diabetologia

Volumn 56, Issue 4, 2013, Pages 901-910

  Luo, P ^a,b   Dematteo, A ^a   Wang, Z ^a   Zhu, L ^c,d   Wang, A ^e   Kim, H S ^f   Pozzi, A ^c,d   Stafford, J M ^c,d   Luther, J M ^a,c  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b Huangshi Central Hospital   (China)

^c VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d DEPARTMENT OF VETERANS AFFAIRS   (United States)

^e EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^f UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Adiponectin; Aldosterone; Aldosterone synthase; Diabetes; Fatty liver; Insulin; Insulin resistance; Insulin secretion; Renin angiotensin aldosterone system

Indexed keywords

ADIPONECTIN; ALDOSTERONE; ALDOSTERONE SYNTHASE; GLUCOSE; INSULIN; TRIACYLGLYCEROL;

ADIPOCYTE; ADIPOSE TISSUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL SIZE; CONTROLLED STUDY; DIET RESTRICTION; FAT CONTENT; FAT MASS; FATTY LIVER; GLUCOSE BLOOD LEVEL; HYPERGLYCEMIA; HYPOALDOSTERONISM; IN VIVO STUDY; INSULIN RELEASE; INSULIN SENSITIVITY; LIPID DIET; MACROPHAGE; MALE; MOUSE; NONHUMAN; OBESITY; PRIORITY JOURNAL; WEIGHT GAIN; WILD TYPE;

ADIPOCYTES; ADIPONECTIN; ADIPOSE TISSUE; ALDOSTERONE; ANIMALS; BLOOD GLUCOSE; BODY COMPOSITION; CONSTRICTION, PATHOLOGIC; DIET, HIGH-FAT; GLUCOSE CLAMP TECHNIQUE; HYPERGLYCEMIA; INSULIN; INSULIN RESISTANCE; LIVER; MACROPHAGES; MALE; MICE; MICE, INBRED C57BL; RANDOM ALLOCATION; SOMATOSTATIN;

EID: 84876476762     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-012-2814-8     Document Type: Article

References (50)

1. Bentley-Lewis R, Adler GK, Perlstein T et al (2007) Body mass index predicts aldosterone production in normotensive adults on a high-salt diet. J Clin Endocrinol Metab 92:4472-4475
2. Goodfriend TL, Kelley DE, Goodpaster BH, Winters SJ (1999) Visceral obesity and insulin resistance are associated with plasma aldosterone levels in women. Obes Res 7:355-362
3. Vasan RS, Evans JC, Larson MG et al (2004) Serum aldosterone and the incidence of hypertension in nonhypertensive persons. N Engl J Med 351:33-41
4. Ingelsson E, Pencina MJ, Tofler GH et al (2007) Multimarker approach to evaluate the incidence of the metabolic syndrome and longitudinal changes in metabolic risk factors: the Framingham Offspring Study. Circulation 116:984-992
5. Sowers JR, Whaley-Connell A, Epstein M (2009) Narrative review: the emerging clinical implications of the role of aldosterone in the metabolic syndrome and resistant hypertension. Ann Intern Med 150:776-783
6. Briet M, Schiffrin EL (2011) The role of aldosterone in the metabolic syndrome. Curr Hypertens Rep 13:163-172
7. Bosch J, Yusuf S, Gerstein HC et al (2006) Effect of ramipril on the incidence of diabetes. N Engl J Med 355:1551-1562
8. McMurray JJ, Holman RR, Haffner SM et al (2010) Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med 362:1477-1490
9. Kahn SE, Hull RL, Utzschneider KM (2006) Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature 444:840-846
10. Weyer C, Bogardus C, Mott DM, Pratley RE (1999) The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest 104:787-794
11. Guo C, Ricchiuti V, Lian BQ et al (2008) Mineralocorticoid receptor blockade reverses obesity-related changes in expression of adiponectin, peroxisome proliferator-activated receptor-gamma, and proinflammatory adipokines. Circulation 117:2253-2261
12. Lastra G, Whaley-Connell A, Manrique C et al (2008) Low-dose spironolactone reduces reactive oxygen species generation and improves insulin-stimulated glucose transport in skeletal muscle in the TG(mRen2)27 rat. Am J Physiol Endocrinol Metab 295:E110-E116
13. Festa A, Williams K, Hanley AJ, Haffner SM (2008) Beta-cell dysfunction in subjects with impaired glucose tolerance and early type 2 diabetes: comparison of surrogate markers with first-phase insulin secretion from an intravenous glucose tolerance test. Diabetes 57:1638-1644
14. Jensen CC, Cnop M, Hull RL, Fujimoto WY, Kahn SE (2002) Beta-cell function is a major contributor to oral glucose tolerance in high-risk relatives of four ethnic groups in the U.S. Diabetes 51:2170-2178
15. Billings LK, Florez JC (2010) The genetics of type 2 diabetes: what have we learned from GWAS? Ann N Y Acad Sci 1212:59-77
16. Mosso LM, Carvajal CA, Maiz A et al (2007) A possible association between primary aldosteronism and a lower beta-cell function. J Hypertens 25:2125-2130
17. Conn JW (1965) Hypertension, the potassium ion and impaired carbohydrate tolerance. N Engl J Med 273:1135-1143
18. Luther JM, Luo P, Kreger MT et al (2011) Aldosterone decreases glucose-stimulated insulin secretion in vivo in mice and in murine islets. Diabetologia 54:2152-2163
19. Ayala JE, Bracy DP, McGuinness OP, Wasserman DH (2006) Considerations in the design of hyperinsulinemic-euglycemic clamps in the conscious mouse. Diabetes 55:390-397
20. Bobbert T, Rochlitz H, Wegewitz U et al (2005) Changes of adiponectin oligomer composition by moderate weight reduction. Diabetes 54:2712-2719
21. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW Jr (2003) Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 112:1796-1808
22. Wu K, Cappel D, Martinez M, Stafford JM (2010) Impaired-inactivation of FoxO1 contributes to glucose-mediated increases in serum very low-density lipoprotein. Endocrinology 151:3566-3576
23. Meneilly GS, McIntosh CH, Pederson RA et al (2001) Effect of glucagon-like peptide 1 on non-insulin-mediated glucose uptake in the elderly patient with diabetes. Diabetes Care 24:1951-1956
24. Turban S, Liu X, Ramage L et al (2012) Optimal elevation of beta-cell 11beta-hydroxysteroid dehydrogenase type 1 is a compensatory mechanism that prevents high-fat diet-induced beta-cell failure. Diabetes 61:642-652
25. Shafrir E, Ziv E, Mosthaf L (1999) Nutritionally induced insulin resistance and receptor defect leading to beta-cell failure in animal models. Ann N Y Acad Sci 892:223-246
26. Ingelsson E, Langenberg C, Hivert MF et al (2010) Detailed physiologic characterization reveals diverse mechanisms for novel genetic Loci regulating glucose and insulin metabolism in humans. Diabetes 59:1266-1275
27. Bellili NM, Foucan L, Fumeron F et al (2010) Associations of the -344 T>C and the 3097 G>A polymorphisms of CYP11B2 gene with hypertension, type 2 diabetes, and metabolic syndrome in a French population. Am J Hypertens 23:660-667
28. Ranade K, Wu KD, Risch N et al (2001) Genetic variation in aldosterone synthase predicts plasma glucose levels. Proc Natl Acad Sci U S A 98:13219-13224
29. Russo P, Lauria F, Loguercio M et al (2007) 344C/T Variant in the promoter of the aldosterone synthase gene (CYP11B2) is associated with metabolic syndrome in men. Am J Hypertens 20:218-222
30. Ho JT, Keogh JB, Bornstein SR et al (2007) Moderate weight loss reduces renin and aldosterone but does not influence basal or stimulated pituitary-adrenal axis function. Horm Metab Res 39:694-699
31. Tuck ML, Sowers J, Dornfeld L, Kledzik G, Maxwell M (1981) The effect of weight reduction on blood pressure, plasma renin activity, and plasma aldosterone levels in obese patients. N Engl J Med 304:930-933
32. Nagase M, Yoshida S, Shibata S et al (2006) Enhanced aldosterone signaling in the early nephropathy of rats with metabolic syndrome: possible contribution of fat-derived factors. J Am Soc Nephrol 17:3438-3446
33. Hall JE, Brands MW, Dixon WN, Smith MJ Jr (1993) Obesity-induced hypertension. Renal function and systemic hemodynamics. Hypertension 22:292-299
34. Goodfriend TL, Ball DL, Egan BM, Campbell WB, Nithipatikom K (2004) Epoxy-keto derivative of linoleic acid stimulates aldosterone secretion. Hypertension 43:358-363
35. Ehrhart-Bornstein M, Lamounier-Zepter V, Schraven A et al (2003) Human adipocytes secrete mineralocorticoid-releasing factors. Proc Natl Acad Sci U S A 100:14211-14216
36. Briones AM, Cat AN, Callera GE et al (2012) Adipocytes produce aldosterone through calcineurin-dependent signaling pathways: implications in diabetes mellitus-associated obesity and vascular dysfunction. Hypertension 59:1069-1078
37. Marzolla V, Armani A, Zennaro MC et al (2012) The role of the mineralocorticoid receptor in adipocyte biology and fat metabolism. Mol Cell Endocrinol 350:281-288
38. Geer EB, Shen W, Strohmayer E, Post KD, Freda PU (2012) Body composition and cardiovascular risk markers after remission of Cushing's disease: a prospective study using whole-body MRI. J Clin Endocrinol Metab 97:1702-1711
39. Masuzaki H, Paterson J, Shinyama H et al (2001) A transgenic model of visceral obesity and the metabolic syndrome. Science 294:2166-2170
40. Hughes KA, Manolopoulos KN, Iqbal J et al (2012) Recycling between cortisol and cortisone in human splanchnic, subcutaneous adipose, and skeletal muscle tissues in vivo. Diabetes 61:1357-1364
41. Sun K, Kusminski CM, Scherer PE (2011) Adipose tissue remodeling and obesity. J Clin Invest 121:2094-2101
42. Li P, Zhang XN, Pan CM et al (2011) Aldosterone perturbs adiponectin and PAI-1 expression and secretion in 3T3-L1 adipocytes. Horm Metab Res 43:464-469
43. Hirata A, Maeda N, Nakatsuji H et al (2012) Contribution of glucocorticoid-mineralocorticoid receptor pathway on the obesity-related adipocyte dysfunction. Biochem Biophys Res Commun 419:182-187
44. Kim JY, van de Wall E, Laplante M et al (2007) Obesity-associated improvements in metabolic profile through expansion of adipose tissue. J Clin Invest 117:2621-2637
45. Wada T, Kenmochi H, Miyashita Y et al (2010) Spironolactone improves glucose and lipid metabolism by ameliorating hepatic steatosis and inflammation and suppressing enhanced gluconeogenesis induced by high-fat and high-fructose diet. Endocrinology 151:2040-2049
46. Kumagai E, Adachi H, Jacobs DR Jr et al (2011) Plasma aldosterone levels and development of insulin resistance: prospective study in a general population. Hypertension 58:1043-1048
47. Gathercole LL, Stewart PM (2010) Targeting the pre-receptor metabolism of cortisol as a novel therapy in obesity and diabetes. J Steroid Biochem Mol Biol 122:21-27
48. Morgan SA, Sherlock M, Gathercole LL et al (2009) 11beta-hydroxysteroid dehydrogenase type 1 regulates glucocorticoid-induced insulin resistance in skeletal muscle. Diabetes 58:2506-2515
49. Wallace TM, Levy JC, Matthews DR (2004) Use and abuse of HOMA modeling. Diabetes Care 27:1487-1495
50. Calhoun DA, White WB, Krum H et al (2011) Effects of a novel aldosterone synthase inhibitor for treatment of primary hypertension: results of a randomized, double-blind, placebo- and active-controlled phase 2 trial. Circulation 124:1945-1955